Valo Health Strikes AI-Driven Parkinson’s Drug Discovery Pact With Merck KGaA, Darmstadt, Germany in Deal Worth Over $3 Billion
Valo Health has announced a landmark collaboration with Merck KGaA, Darmstadt, Germany, aimed at accelerating the discovery and development of new therapeutics for Parkinson’s disease and related neurological disorders, using Valo’s AI-enabled human causal biology and closed-loop chemistry platforms. The partnership includes upfront and milestone payments exceeding $3 billion, representing one of the largest AI-drug-discovery tie-ups in the neurodegeneration space to date.
Merck KGaA, Darmstadt, Germany a company with deep roots in neurology and immunology, the deal is a strategic bet on AI-integrated R&D to sharpen target discovery and compress early development timelines. For Valo, it is a validation of its real-world-data-driven approach, which leverages millions of human biological datapoints to identify, characterize, and validate disease mechanisms in heterogeneous neurological conditions.
What You Need To Know
- Valo Health and Merck KGaA, Darmstadt, Germany enter a collaboration worth over $3B for AI-enabled Parkinson’s drug discovery.
- Valo’s platform leverages 17M+ patient records and closed-loop chemistry to identify and optimize human-validated targets.
- Partnership aims to accelerate and de-risk early-stage neurology pipelines with AI-powered discovery.
- Deal reflects growing pharma reliance on real-world, multimodal human datasets for neurodegenerative R&D.
AI Meets Human Biology: A Powerful Combination for Parkinson’s Drug Discovery
A central component of the collaboration is Valo’s human causal biology platform, built on access to more than 17 million de-identified patient records, some spanning up to 30 years, as well as biobank samples. Using this dataset, Valo applies advanced machine learning to detect disease patterns, map progression, cluster patient subtypes, and identify novel therapeutic targets grounded directly in human evidence.
In Parkinson’s disease a condition defined by complexity, phenotypic variation, and incomplete mechanistic understanding this approach is particularly compelling. Traditional models often fail to capture pathophysiological diversity, leading many once-promising neurodegeneration candidates to collapse in late development.
“Starting with human causal biology in vast amounts of real-world data allows us to unravel the complexity of heterogeneous diseases like Parkinson’s,” said Brian Alexander, MD, MPH, CEO of Valo Health. He noted that the approach increases the likelihood that early-stage targets translate into clinical therapeutic effects a long-standing challenge in Parkinson’s drug development.
Once targets are identified, Valo’s closed-loop chemistry platform rapidly generates, optimizes, and evaluates preclinical small-molecule candidates from trillions of possible starting points. The combination of mechanistic human-data grounding and high-speed optimization creates what Valo describes as an “R&D engine built for precision, velocity, and translatability.”
Merck KGaA’s R&D leadership emphasized the opportunity to accelerate the next wave of neurology assets.
“Valo Health’s AI-enabled platforms utilizing human data will help sharpen target selection and streamline drug discovery,” said Amy Kao, Global Head of Neurology & Immunology Research Unit. “Our research engine is focused on delivering meaningful medicines for patients with high unmet medical needs.”
Parkinson’s disease remains an area of substantial unmet need, with no disease-modifying therapy approved and most treatments focused on symptomatic relief. For pharmaceutical companies with strong neurology brands, expanding into next-generation neurodegenerative therapeutics is both a scientific imperative and a market opportunity, particularly as AI technologies unlock new target classes previously impossible to identify.
The deal also complements Merck KGaA’s broader strategy of integrating external innovation with internal development scale a model that has underpinned several of its neuroscience pipeline investments.
Related news
Scilex Secures Exclusive Global License for Tokenizing Biotech Assets Through Datavault AI Platform
A Dual-Track Strategy for Valo: Internal Pipeline + Big-Pharma Partnerships
Valo Health continues to pursue a dual strategy:
• advancing internal pipeline assets across multiple disease areas, and
• partnering with large pharmaceutical companies to accelerate preclinical R&D through shared capabilities.
The collaboration with Merck KGaA, Darmstadt, Germany is emblematic of the second track pairing Valo’s discovery technologies with a partner capable of global clinical development and commercial execution.
By combining Valo’s AI-driven early-stage discovery with Merck KGaA’s late-stage development infrastructure, the companies expect to shorten discovery cycles, reduce attrition, and increase the probability of delivering first-in-class or best-in-class Parkinson’s candidates.
With pharma companies increasingly embracing AI as an essential component of modern R&D, the Valo–Merck KGaA, Darmstadt, Germany deal highlights several emerging themes:
• Human-data–first target discovery is becoming a competitive differentiator in neurodegeneration.
• Multimodal data (clinical, imaging, genomic, tissue models) is now central to early target validation.
• Closed-loop chemistry and generative platforms are shifting timelines for preclinical small-molecule development.
• AI collaborations are rapidly scaling in financial size, scientific ambition, and breadth of application.
The companies did not disclose specific targets or therapeutic mechanisms being pursued, but the scale and structure of the partnership indicate a multi-program pipeline strategy rather than a single-asset collaboration.